Feature

For decades, metformin has been the backbone of type 2 diabetes therapy. As we move through 2026, the future of metformin in type 2 diabetes treatment is under fresh scrutiny. Should it still be the first-line agent, or have newer drug classes like GLP‑1 receptor agonists and SGLT2 inhibitors earned …

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

With the release of the ADA 2026 diabetes sleep guidelines, the American Diabetes Association has officially elevated sleep and circadian rhythm health to core pillars of diabetes care—right alongside nutrition, physical activity, and medication. These new standards mark a significant shift toward more holistic and behavioral-focused approaches to managing diabetes. …

The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes. These therapies, originally developed for glucose control, now show robust benefits in weight management. However, as use becomes more common in clinical practice, endocrinologists and primary care providers must balance glycemic outcomes, weight …

Diabetes doesn’t look the same for every patient—so why should the care plan? Culturally tailored diabetes care recognizes that one-size-fits-all approaches often fall short in reaching patients from different backgrounds. Whether it’s language, food traditions, or health beliefs, culture plays a critical role in diabetes self-management. This article explores how …